HARIS ZAHOOR to Male
This is a "connection" page, showing publications HARIS ZAHOOR has written about Male.
Connection Strength
0.143
-
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. Invest New Drugs. 2019 12; 37(6):1231-1238.
Score: 0.024
-
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018 10 17; 6(1):107.
Score: 0.023
-
Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. Medicine (Baltimore). 2018 Sep; 97(37):e12344.
Score: 0.023
-
Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442.
Score: 0.022
-
The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am J Surg. 2015 Oct; 210(4):610-7.
Score: 0.018
-
A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg. 2015 Feb; 149(2):538-47.
Score: 0.018
-
Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892.
Score: 0.006
-
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319.
Score: 0.005
-
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-a but Not Observation in Intermediate Risk Melanoma Patients. PLoS One. 2015; 10(7):e0132745.
Score: 0.005